COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Jaguar Health announces Orphan Drug Designation application for crofelemer for symptomatic relief and treatment of moderate-to-severe diarrhea caused by bacterial, viral, and parasitic infections, including cholera. Crofelemer is a novel plant-based prescription drug derived from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest -
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Magdalena Biosciences, Inc. plans to submit an Investigational New Drug application to the FDA in 2024 for a next-generation psychoactive prescription drug candidate targeting mental health indications such as ADHD, depression, and anxiety. The preclinical study in mice suggests psychoactive activity in a plant extract for potential use as a next-generation psychoactive prescription drug. Magdalena focuses on identifying safe and effective plant-based psychoactive drugs to treat mental health disorders -
COMMUNIQUÉ DE PRESSE
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
Jaguar Health, Inc. (NASDAQ:JAGX) founder Lisa Conte to present at The Microcap Conference on January 31, 2024 in Atlantic City, NJ and participate in a fireside chat and one-on-one meetings at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. For more information visit jaguar.health -
COMMUNIQUÉ DE PRESSE
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the publication of a study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor neratinib (Nerlynx®) in female dogs. The study, conducted by Napo Pharmaceuticals in collaboration with Puma Biotechnology, highlights the growing need for treatment of cancer therapy-related diarrhea (CTD), a common and debilitating side effect of patients undergoing cancer therapy. The findings of this study, along with two other important studies, provide scientific rationale for the use of crofelemer in humans for the prevention and treatment of CTD, addressing the unmet medical need in the age of targeted cancer therapies. -
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted 7,500 restricted stock units (RSUs) to a new employee, with vesting over three years. The RSUs were approved by the Compensation Committee of Jaguar's Board and are subject to the employee's continued service. Jaguar Health is a pharmaceutical company focused on developing prescription medicines derived from plants for gastrointestinal distress. -
COMMUNIQUÉ DE PRESSE
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
Napo Pharmaceuticals, a Jaguar Health family company, has received a new U.S. patent for methods to treat congenital diarrheal disorders with crofelemer, their novel plant-based prescription drug. This patent enhances their intellectual property protection for crofelemer and supports their focus on rare disease indications such as microvillus inclusion disease and short bowel syndrome. Jaguar is conducting investigator-initiated studies for these rare disease indications in multiple regions with results expected in 2024. -
-
-
COMMUNIQUÉ DE PRESSE
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Napo Pharmaceuticals and Advocates for Collaborative Education (ACE) have released the abstract for a quality of life survey for individuals with a cancer diagnosis, shedding light on the challenges faced. The survey findings will be presented at the December 2023 SABCS, focusing on the impacts of cancer diagnosis and treatment on quality of life, including physical and emotional well-being, treatment side effects, and the consequences of managing those side effects
